522 related articles for article (PubMed ID: 15452254)
1. Small molecules blocking the entry of severe acute respiratory syndrome coronavirus into host cells.
Yi L; Li Z; Yuan K; Qu X; Chen J; Wang G; Zhang H; Luo H; Zhu L; Jiang P; Chen L; Shen Y; Luo M; Zuo G; Hu J; Duan D; Nie Y; Shi X; Wang W; Han Y; Li T; Liu Y; Ding M; Deng H; Xu X
J Virol; 2004 Oct; 78(20):11334-9. PubMed ID: 15452254
[TBL] [Abstract][Full Text] [Related]
2. Emodin blocks the SARS coronavirus spike protein and angiotensin-converting enzyme 2 interaction.
Ho TY; Wu SL; Chen JC; Li CC; Hsiang CY
Antiviral Res; 2007 May; 74(2):92-101. PubMed ID: 16730806
[TBL] [Abstract][Full Text] [Related]
3. The anti-HIV drug nelfinavir mesylate (Viracept) is a potent inhibitor of cell fusion caused by the SARSCoV-2 spike (S) glycoprotein warranting further evaluation as an antiviral against COVID-19 infections.
Musarrat F; Chouljenko V; Dahal A; Nabi R; Chouljenko T; Jois SD; Kousoulas KG
J Med Virol; 2020 Oct; 92(10):2087-2095. PubMed ID: 32374457
[TBL] [Abstract][Full Text] [Related]
4. Identification of a broad-spectrum antiviral small molecule against severe acute respiratory syndrome coronavirus and Ebola, Hendra, and Nipah viruses by using a novel high-throughput screening assay.
Elshabrawy HA; Fan J; Haddad CS; Ratia K; Broder CC; Caffrey M; Prabhakar BS
J Virol; 2014 Apr; 88(8):4353-65. PubMed ID: 24501399
[TBL] [Abstract][Full Text] [Related]
5. Amino acids 270 to 510 of the severe acute respiratory syndrome coronavirus spike protein are required for interaction with receptor.
Babcock GJ; Esshaki DJ; Thomas WD; Ambrosino DM
J Virol; 2004 May; 78(9):4552-60. PubMed ID: 15078936
[TBL] [Abstract][Full Text] [Related]
6. Severe acute respiratory syndrome coronavirus entry as a target of antiviral therapies.
Kuhn JH; Li W; Radoshitzky SR; Choe H; Farzan M
Antivir Ther; 2007; 12(4 Pt B):639-50. PubMed ID: 17944271
[TBL] [Abstract][Full Text] [Related]
7. Pseudotyped vesicular stomatitis virus for analysis of virus entry mediated by SARS coronavirus spike proteins.
Fukushi S; Watanabe R; Taguchi F
Methods Mol Biol; 2008; 454():331-8. PubMed ID: 19057867
[TBL] [Abstract][Full Text] [Related]
8. Pathways of cross-species transmission of synthetically reconstructed zoonotic severe acute respiratory syndrome coronavirus.
Sheahan T; Rockx B; Donaldson E; Corti D; Baric R
J Virol; 2008 Sep; 82(17):8721-32. PubMed ID: 18579604
[TBL] [Abstract][Full Text] [Related]
9. Chloroquine is a potent inhibitor of SARS coronavirus infection and spread.
Vincent MJ; Bergeron E; Benjannet S; Erickson BR; Rollin PE; Ksiazek TG; Seidah NG; Nichol ST
Virol J; 2005 Aug; 2():69. PubMed ID: 16115318
[TBL] [Abstract][Full Text] [Related]
10. Identification of critical determinants on ACE2 for SARS-CoV entry and development of a potent entry inhibitor.
Han DP; Penn-Nicholson A; Cho MW
Virology; 2006 Jun; 350(1):15-25. PubMed ID: 16510163
[TBL] [Abstract][Full Text] [Related]
11. Efficient activation of the severe acute respiratory syndrome coronavirus spike protein by the transmembrane protease TMPRSS2.
Matsuyama S; Nagata N; Shirato K; Kawase M; Takeda M; Taguchi F
J Virol; 2010 Dec; 84(24):12658-64. PubMed ID: 20926566
[TBL] [Abstract][Full Text] [Related]
12. Fusion core structure of the severe acute respiratory syndrome coronavirus (SARS-CoV): in search of potent SARS-CoV entry inhibitors.
Chu LH; Chan SH; Tsai SN; Wang Y; Cheng CH; Wong KB; Waye MM; Ngai SM
J Cell Biochem; 2008 Aug; 104(6):2335-47. PubMed ID: 18442051
[TBL] [Abstract][Full Text] [Related]
13. Differential downregulation of ACE2 by the spike proteins of severe acute respiratory syndrome coronavirus and human coronavirus NL63.
Glowacka I; Bertram S; Herzog P; Pfefferle S; Steffen I; Muench MO; Simmons G; Hofmann H; Kuri T; Weber F; Eichler J; Drosten C; Pöhlmann S
J Virol; 2010 Jan; 84(2):1198-205. PubMed ID: 19864379
[TBL] [Abstract][Full Text] [Related]
14. S protein of severe acute respiratory syndrome-associated coronavirus mediates entry into hepatoma cell lines and is targeted by neutralizing antibodies in infected patients.
Hofmann H; Hattermann K; Marzi A; Gramberg T; Geier M; Krumbiegel M; Kuate S; Uberla K; Niedrig M; Pöhlmann S
J Virol; 2004 Jun; 78(12):6134-42. PubMed ID: 15163706
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of SARS-CoV replication by siRNA.
Wu CJ; Huang HW; Liu CY; Hong CF; Chan YL
Antiviral Res; 2005 Jan; 65(1):45-8. PubMed ID: 15652970
[TBL] [Abstract][Full Text] [Related]
16. Antiviral activity of nucleoside analogues against SARS-coronavirus (SARS-coV).
Chu CK; Gadthula S; Chen X; Choo H; Olgen S; Barnard DL; Sidwell RW
Antivir Chem Chemother; 2006; 17(5):285-9. PubMed ID: 17176633
[TBL] [Abstract][Full Text] [Related]
17. Severe acute respiratory syndrome coronavirus (SARS-CoV) infection inhibition using spike protein heptad repeat-derived peptides.
Bosch BJ; Martina BE; Van Der Zee R; Lepault J; Haijema BJ; Versluis C; Heck AJ; De Groot R; Osterhaus AD; Rottier PJ
Proc Natl Acad Sci U S A; 2004 Jun; 101(22):8455-60. PubMed ID: 15150417
[TBL] [Abstract][Full Text] [Related]
18. Design and biological activities of novel inhibitory peptides for SARS-CoV spike protein and angiotensin-converting enzyme 2 interaction.
Ho TY; Wu SL; Chen JC; Wei YC; Cheng SE; Chang YH; Liu HJ; Hsiang CY
Antiviral Res; 2006 Feb; 69(2):70-6. PubMed ID: 16337697
[TBL] [Abstract][Full Text] [Related]
19. Cleavage of the SARS coronavirus spike glycoprotein by airway proteases enhances virus entry into human bronchial epithelial cells in vitro.
Kam YW; Okumura Y; Kido H; Ng LF; Bruzzone R; Altmeyer R
PLoS One; 2009 Nov; 4(11):e7870. PubMed ID: 19924243
[TBL] [Abstract][Full Text] [Related]
20. Roles of spike protein in the pathogenesis of SARS coronavirus.
Jin DY; Zheng BJ
Hong Kong Med J; 2009 Feb; 15 Suppl 2():37-40. PubMed ID: 19258633
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
